Technical Analysis for MPH - Medicure Inc.

Grade Last Price % Change Price Change
F 0.880 0.00% 0.000
MPH closed unchanged on Tuesday, November 19, 2024, on 27 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Earnings Movers Other 0.00%
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Gapped Down Weakness 0.00%
Fell Below 50 DMA Bearish -11.11%
Expansion Pivot Sell Setup Bearish Swing Setup -11.11%

   Recent Intraday Alerts

Alert Time
Down 2 ATRs 15 days ago
Down 1 ATR 15 days ago
Slingshot Bearish Entry 15 days ago
Fell Below Previous Day's Low 15 days ago
Outside Day 15 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Medicure Inc. Description

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Marketing Medicine Pharma Pharmaceutical Clinic Drug Skin Biopharmaceutical Organ Systems Pharmaceutical Industry Disorders Cardiology Neurological Disorders

Is MPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.8
52 Week Low 0.84
Average Volume 4,428
200-Day Moving Average 1.267
50-Day Moving Average 1.038
20-Day Moving Average 0.963
10-Day Moving Average 0.922
Average True Range 0.068
RSI (14) 42.53
ADX 8.11
+DI 32.569
-DI 34.391
Chandelier Exit (Long, 3 ATRs) 0.945
Chandelier Exit (Short, 3 ATRs) 1.045
Upper Bollinger Bands 1.091
Lower Bollinger Band 0.836
Percent B (%b) 0.17
BandWidth 26.480
MACD Line -0.035
MACD Signal Line -0.034
MACD Histogram -0.0011
Fundamentals Value
Market Cap 9.2 Million
Num Shares 10.5 Million
EPS -0.18
Price-to-Earnings (P/E) Ratio -5.00
Price-to-Sales 0.79
Price-to-Book 0.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.880
Resistance 3 (R3) 0.880 0.880 0.880
Resistance 2 (R2) 0.880 0.880 0.880 0.880
Resistance 1 (R1) 0.880 0.880 0.880 0.880 0.880
Pivot Point 0.880 0.880 0.880 0.880 0.880
Support 1 (S1) 0.880 0.880 0.880 0.880 0.880
Support 2 (S2) 0.880 0.880 0.880 0.880
Support 3 (S3) 0.880 0.880 0.880
Support 4 (S4) 0.880